ReviewDeutsches Arzteblatt international2026
The Proposed Introduction of a Prostate Cancer Screening Program in Germany: Procedure, Necessary Studies before Implementation, Benefits, and Risks.
Review in Deutsches Arzteblatt international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBoth the new German S3 guideline on prostate cancer (2025) and the European Union (2022) recommend risk-adapted early detection of prostate cancer by measurement of the prostate-specific antigen (PSA) level combined with magnetic resonance imaging (MRI).In this article, we describe the available screening instruments and the implications of various different methods that might be used for the introduction of a prostate cancer screening program in Germany.
methodsThis narrative review is based on pertinent publications that were retrieved by a literature search from November 2024 to November 2025.
resultsCompared to purely PSA-based screening, a PSA-based, risk-adapted screening program lowers the incidence of clinically indolent prostate cancer (ISUP gradation group 1) from approximately 50% to 24% if begun at age 45-50. The cumulative incidence of clinically relevant prostate cancer is 0.6% and thus comparable to the detection rate of breast cancer screening in patients of this age group. Prostate cancer screening starting at an older age increases the number of overdiagnoses leading to unnecessary treatment and is in all likelihood not cost-efficient.
conclusionProstate cancer screening that starts at age 45-50 and proceeds on the basis of a risk-adapted concept has a better benefit-to-harm ratio than a screening program introduced all at once over a wide age range (e.g., 50-70) or opportunistic screening (i.e., no organized screening program). Implementation studies and model calculations on cost-efficiency are needed before organized screening can begin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.